1. Home
  2. LASR vs ADPT Comparison

LASR vs ADPT Comparison

Compare LASR & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo nLIGHT Inc.

LASR

nLIGHT Inc.

HOLD

Current Price

$37.11

Market Cap

4.1B

Sector

Technology

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$25.55

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LASR
ADPT
Founded
2000
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
4.5B
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
LASR
ADPT
Price
$37.11
$25.55
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
9
Target Price
★ $82.13
$29.81
AVG Volume (30 Days)
806.4K
★ 2.1M
Earning Date
11-05-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
62.99
★ 63.89
EPS
★ N/A
N/A
Revenue
$191,359,000.00
★ $276,976,000.00
Revenue This Year
$17.05
$5.94
Revenue Next Year
$13.92
$22.42
P/E Ratio
★ N/A
N/A
Revenue Growth
38.09
★ 54.77
52 Week Low
$28.05
$12.00
52 Week High
$86.95
$30.74

Technical Indicators

Market Signals
Indicator
LASR
ADPT
Relative Strength Index (RSI) 42.81 47.38
Support Level N/A $23.73
Resistance Level $41.42 $26.51
Average True Range (ATR) 1.77 1.44
MACD 0.07 -0.34
Stochastic Oscillator 47.74 25.47

Price Performance

Historical Comparison
LASR
ADPT

About LASR nLIGHT Inc.

nLight Inc is a United States-based company provider of power semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It designs, manufactures, and sells a range of power semiconductor lasers and fiber lasers that are typically integrated into laser systems. It operates in two segments: Laser Products segment, which includes semiconductor lasers, fiber lasers, and directed energy products; and Advanced Development segment includes revenue earned from research and development contracts. The majority of its revenue is generated from the Laser segment. The company's geographical segments include North America, Asia Pacific, and EMEA, of which maximum revenue is derived from North America.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: